NXP900 Enhances Osimertinib’s Effectiveness In EGFR-Mutated NSCLC, Showing Promising Results As Combination Therapy

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing precision therapies for oncology, has announced a new publication from Prof. Ruth Keri’s laboratory at Cleveland Clinic. The research was conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University). The study highlights the enhanced effectiveness of NXP900, together with osimertinib is the active component of Tagrisso®, in treating Epidermal Growth Factor Receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). In an in vivo model, the combination outperformed osimertinib alone, demonstrating reduced cancer cell proliferation and increased apoptosis in vitro. 

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "As we continue our activities toward the initiation of the Phase 1b program of NXP900, we are very pleased to see yet another independently generated dataset from a highly reputable research institution demonstrating the synergistic effect of adding NXP900 to osimertinib in EGFR mutated NSCLC. With the Phase 1a dose escalation study nearing completion, we are excited about the potential opportunities presented by NXP900 in therapeutic areas of unmet medical need, both as a single agent and in combination with market-leading anti-cancer drugs."

The published data, appearing in Molecular Cancer Research (Cuellar-Vite et al., 2025), strengthens the mechanistic rationale for using NXP900 in combination with EGFR inhibitors in the treatment of EGFR-mutated cancers. The study supports the potential benefits of this combination approach in overcoming treatment resistance, which is a major challenge in NSCLC therapy. These findings provide additional scientific validation for integrating NXP900 with existing EGFR-targeted treatments. Additionally, the research aligns with earlier findings from AstraZeneca, which previously demonstrated that adding NXP900 to osimertinib could reverse drug resistance in osimertinib-resistant cell lines.